Front Cover: Novel 4,5-Dihydrothiazole-Phenylpiperazine Derivatives: Synthesis, Docking Studies and Pharmacological Evaluation as Serotonergic Agents (ChemMedChem 15/2025)

IF 3.4 4区医学 Q2 CHEMISTRY, MEDICINAL

ChemMedChem Pub Date : 2025-08-04 DOI:10.1002/cmdc.70006

Giorgia Andreozzi, Natalia Karkoszka, Rosa Sparaco, Angela Corvino, Beatrice Severino, Vincenzo Santagada, Elisa Magli, Ewa Gibuła-Tarłowska, Jolanta H. Kotlińska, Kinga Gawel, Raffaele Capasso, Anna Lesniak, Nataliia Semenko, Agnieszka A. Kaczor, Anna Bielenica, Grażyna Biała, Giuseppe Caliendo, Ewa Kędzierska, Ferdinando Fiorino

{"title":"Front Cover: Novel 4,5-Dihydrothiazole-Phenylpiperazine Derivatives: Synthesis, Docking Studies and Pharmacological Evaluation as Serotonergic Agents (ChemMedChem 15/2025)","authors":"Giorgia Andreozzi, Natalia Karkoszka, Rosa Sparaco, Angela Corvino, Beatrice Severino, Vincenzo Santagada, Elisa Magli, Ewa Gibuła-Tarłowska, Jolanta H. Kotlińska, Kinga Gawel, Raffaele Capasso, Anna Lesniak, Nataliia Semenko, Agnieszka A. Kaczor, Anna Bielenica, Grażyna Biała, Giuseppe Caliendo, Ewa Kędzierska, Ferdinando Fiorino","doi":"10.1002/cmdc.70006","DOIUrl":null,"url":null,"abstract":"The cover image depicts the ligand–receptor complexes of the most attractive synthesized ligands, FG-7 and FG-18 derivatives, within the 5-HT1A and 5-HT2C receptor subtypes. They are shown inside a brain, highlighting the in vivo assay results: FG-7 showed anxiolytic effects along with pro-cognitive properties, while FG-18, characterized by strong affinity and selectivity for the 5-HT2C receptor, also demonstrated a marked anxiolytic profile. The results emerging from the performed assays suggest that both FG-7 and FG-18 are promising candidates for further development. More details can be found in the research article 10.1002/cmdc.202500288 by Ferdinando Fiorino and co-workers.\n <figure>\n <div><picture>\n <source></source></picture>\n </div>\n </figure>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":"20 15","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cmdc.70006","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cmdc.70006","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}

引用次数: 0

Abstract

The cover image depicts the ligand–receptor complexes of the most attractive synthesized ligands, FG-7 and FG-18 derivatives, within the 5-HT_1A and 5-HT_2C receptor subtypes. They are shown inside a brain, highlighting the in vivo assay results: FG-7 showed anxiolytic effects along with pro-cognitive properties, while FG-18, characterized by strong affinity and selectivity for the 5-HT_2C receptor, also demonstrated a marked anxiolytic profile. The results emerging from the performed assays suggest that both FG-7 and FG-18 are promising candidates for further development. More details can be found in the research article 10.1002/cmdc.202500288 by Ferdinando Fiorino and co-workers.

Abstract Image

查看原文本刊更多论文

封面：新型4,5-二氢噻唑-苯哌嗪衍生物：合成、对接研究和作为血清素能剂的药理学评价（ChemMedChem 15/2025）

封面图片描绘了5-HT1A和5-HT2C受体亚型中最吸引人的合成配体FG-7和FG-18衍生物的配体-受体复合物。它们显示在大脑内，突出了体内实验结果：FG-7显示出抗焦虑作用以及促进认知特性，而FG-18具有对5-HT2C受体的强亲和力和选择性，也显示出明显的抗焦虑特征。实验结果表明，FG-7和FG-18都具有进一步开发的潜力。更多细节可以在研究文章10.1002/ cmc中找到。202500288，作者：ferdinand Fiorino及其同事。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ChemMedChem 医学-药学

CiteScore

6.70

自引率

2.90%

发文量

280

审稿时长

1 months

期刊介绍： Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.